Graeme Milligan

List of Publications by Year
in descending order

472 papers	27,004 citations	5782 84 h-index	12272 138 g-index
485 all docs	485 docs citations	485 times ranked	20369 citing authors

#	Article	IF	Citations
1	Therapeutic validation of an orphan G proteinâ€coupled receptor: The case of GPR84. British Journal of Pharmacology, 2022, 179, 3529-3541.	2.7	27
2	Agonist-induced phosphorylation of orthologues of the orphan receptor GPR35 functions as an activation sensor. Journal of Biological Chemistry, 2022, 298, 101655.	1.6	22
3	Chemogenetics defines a short-chain fatty acid receptor gutâ€“brain axis. ELife, 2022, 11, .	2.8	21
4	Selective phosphorylation of threonine residues defines GPR84â€“arrestin interactions of biased ligands. Journal of Biological Chemistry, 2022, 298, 101932.	1.6	18
5	The M ₁ muscarinic receptor is present in situ as a ligand-regulated mixture of monomers and oligomeric complexes. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	4
6	Metabolic and inflammatory functions of short-chain fatty acid receptors. Current Opinion in Endocrine and Metabolic Research, 2021, 16, 1-9.	0.6	33
7	Chemokine receptor CXCR4 oligomerization is disrupted selectively by the antagonist ligand IT1t. Journal of Biological Chemistry, 2021, 296, 100139.	1.6	15
8	Chemogenetic Approaches to Explore the Functions of Free Fatty Acid Receptor 2. Trends in Pharmacological Sciences, 2021, 42, 191-202.	4.0	8
9	G-protein coupled receptor 35 (GPR35) regulates the colonic epithelial cell response to enterotoxigenic Bacteroides fragilis. Communications Biology, 2021, 4, 585.	2.0	20
10	Discovery and Characterization of Novel Antagonists of the Proinflammatory Orphan Receptor GPR84. ACS Pharmacology and Translational Science, 2021, 4, 1598-1613.	2.5	11
11	Structureâ€Activity Relationship Explorations and Discovery of a Potent Antagonist for the Free Fatty Acid Receptor 2. ChemMedChem, 2021, 16, 3326-3341.	1.6	2
12	G Protein-Coupled Receptor GPR35 Suppresses Lipid Accumulation in Hepatocytes. ACS Pharmacology and Translational Science, 2021, 4, 1835-1848.	2.5	8
13	Biased M1 muscarinic receptor mutant mice show accelerated progression of prion neurodegenerative disease. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	13
14	Therapeutic Opportunities and Challenges in Targeting the Orphan G Protein-Coupled Receptor GPR35. ACS Pharmacology and Translational Science, 2020, 3, 801-812.	2.5	42
15	Discovery of 9-Cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial. Journal of Medicinal Chemistry, 2020, 63, 13526-13545.	2.9	29
16	Pathophysiological regulation of lung function by the free fatty acid receptor FFA4. Science Translational Medicine, 2020, 12, .	5.8	20
17	Combinatorial expression of GPCR isoforms affects signalling and drug responses. Nature, 2020, 587, 650-656.	13.7	87
18	Structureâ€“Activity Relationship Studies of Tetrahydroquinolone Free Fatty Acid Receptor 3 Modulators. Journal of Medicinal Chemistry, 2020, 63, 3577-3595.	2.9	8

#	Article	IF	Citations
19	Gut Dysbiosis during Influenza Contributes to Pulmonary Pneumococcal Superinfection through Altered Short-Chain Fatty Acid Production. Cell Reports, 2020, 30, 2934-2947.e6.	2.9	221
20	Context-Dependent Signaling of CXC Chemokine Receptor 4 and Atypical Chemokine Receptor 3. Molecular Pharmacology, 2019, 96, 778-793.	1.0	30
21	A general method to quantify ligand-driven oligomerization from fluorescence-based images. Nature Methods, 2019, 16, 493-496.	9.0	47
22	Chemogenetics defines receptor-mediated functions of short chain free fatty acids. Nature Chemical Biology, 2019, 15, 489-498.	3.9	52
23	On-target and off-target effects of novel orthosteric and allosteric activators of GPR84. Scientific Reports, 2019, 9, 1861.	1.6	20
24	Fatty airways: a source of good and bad fats?. European Respiratory Journal, 2019, 54, 1902060.	3.1	3
25	Receptor selectivity between the G proteins GÎ± ₁₂ and GÎ± ₁₃ is defined by a single leucineâ€toâ€isoleucine variation. FASEB Journal, 2019, 33, 5005-5017.	0.2	23
26	GPCR homo-oligomerization. Current Opinion in Cell Biology, 2019, 57, 40-47.	2.6	94
27	Design, Synthesis, and Evaluation of a Diazirine Photoaffinity Probe for Ligand-Based Receptor Capture Targeting G Proteinâ€“Coupled Receptors. Molecular Pharmacology, 2019, 95, 196-209.	1.0	15
28	Free fatty acid receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	2
29	Genome Editing Provides New Insights into Receptor-Controlled Signalling Pathways. Trends in Pharmacological Sciences, 2018, 39, 481-493.	4.0	30
30	Spatial Intensity Distribution Analysis: Studies of G Protein-Coupled Receptor Oligomerisation. Trends in Pharmacological Sciences, 2018, 39, 175-186.	4.0	24
31	G proteinâ€coupled receptors not currently in the spotlight: free fatty acid receptor 2 and GPR35. British Journal of Pharmacology, 2018, 175, 2543-2553.	2.7	22
32	Specific substrate-driven changes in human faecal microbiota composition contrast with functional redundancy in short-chain fatty acid production. ISME Journal, 2018, 12, 610-622.	4.4	173
33	Muscarinic receptor oligomerization. Neuropharmacology, 2018, 136, 401-410.	2.0	15
34	Discovery of a Potent Thiazolidine Free Fatty Acid Receptor 2 Agonist with Favorable Pharmacokinetic Properties. Journal of Medicinal Chemistry, 2018, 61, 9534-9550.	2.9	29
35	Dietary fibers inhibit obesity in mice, but host responses in the cecum and liver appear unrelated to fiber-specific changes in cecal bacterial taxonomic composition. Scientific Reports, 2018, 8, 15566.	1.6	34
36	Structural Characterization of Agonist Binding to Protease-Activated Receptor 2 through Mutagenesis and Computational Modeling. ACS Pharmacology and Translational Science, 2018, 1, 119-133.	2.5	9

#	Article	IF	Citations
37	Evidence for the Existence of a CXCL17 Receptor Distinct from GPR35. Journal of Immunology, 2018, 201, 714-724.	0.4	35
38	The Orphan Receptor GPR35 Contributes to Angiotensin IIâ€"Induced Hypertension and Cardiac Dysfunction in Mice. American Journal of Hypertension, 2018, 31, 1049-1058.	1.0	24
39	The emerging pharmacology and function of GPR35 in the nervous system. Neuropharmacology, 2017, 113, 661-671.	2.0	37
40	Complex Pharmacology of Free Fatty Acid Receptors. Chemical Reviews, 2017, 117, 67-110.	23.0	209
41	Fatty acid 16:4(nâ€3) stimulates a GPR120â€induced signaling cascade in splenic macrophages to promote chemotherapy resistance.. FASEB Journal, 2017, 31, 2195-2209.	0.2	27
42	Probe-Dependent Negative Allosteric Modulators of the Long-Chain Free Fatty Acid Receptor FFA4. Molecular Pharmacology, 2017, 91, 630-641.	1.0	29
43	M3 muscarinic acetylcholine receptor facilitates the endocytosis of mu opioid receptor mediated by morphine independently of the formation of heteromeric complexes. Cellular Signalling, 2017, 35, 208-222.	1.7	4
44	Differential manipulation of arrestin-3 binding to basal and agonist-activated G protein-coupled receptors. Cellular Signalling, 2017, 36, 98-107.	1.7	13
45	Succinct synthesis of saturated hydroxy fatty acids andin vitroevaluation of all hydroxylauric acids on FFA1, FFA4 and GPR84. MedChemComm, 2017, 8, 1360-1365.	3.5	16
46	Spatial intensity distribution analysis quantifies the extent and regulation of homodimerization of the secretin receptor. Biochemical Journal, 2017, 474, 1879-1895.	1.7	31
47	Development and Characterization of a Fluorescent Tracer for the Free Fatty Acid Receptor 2 (FFA2/GPR43). Journal of Medicinal Chemistry, 2017, 60, 5638-5645.	2.9	32
48	The Use of Spatial Intensity Distribution Analysis to Examine G Protein-Coupled Receptor Oligomerization. , 2017, , 15-38.		2
49	A Molecular Basis for Selective Antagonist Destabilization of Dopamine D3 Receptor Quaternary Organization. Scientific Reports, 2017, 7, 2134.	1.6	17
50	FFA4/GPR120: Pharmacology and Therapeutic Opportunities. Trends in Pharmacological Sciences, 2017, 38, 809-821.	4.0	77
51	A single extracellular amino acid in Free Fatty Acid Receptor 2 defines antagonist species selectivity and G protein selection bias. Scientific Reports, 2017, 7, 13741.	1.6	21
52	Modulation of SF1 Neuron Activity Coordinately Regulates Both Feeding Behavior and Associated Emotional States. Cell Reports, 2017, 21, 3559-3572.	2.9	73
53	Three classes of ligands each bind to distinct sites on the orphan G protein-coupled receptor GPR84. Scientific Reports, 2017, 7, 17953.	1.6	50
54	A Novel Allosteric Activator of Free Fatty Acid 2 Receptor Displays Unique Gi-functional Bias. Journal of Biological Chemistry, 2016, 291, 18915-18931.	1.6	66

#	Article	IF	Citations
55	Metabolism meets immunity: The role of free fatty acid receptors in the immune system. Biochemical Pharmacology, 2016, 114, 3-13.	2.0	197
56	The Pharmacology and Function of Receptors for Short-Chain Fatty Acids. Molecular Pharmacology, 2016, 89, 388-398.	1.0	206
57	Non-equivalence of Key Positively Charged Residues of the Free Fatty Acid 2 Receptor in the Recognition and Function of Agonist Versus Antagonist Ligands. Journal of Biological Chemistry, 2016, 291, 303-317.	1.6	49
58	Development and Characterization of a Potent Free Fatty Acid Receptor 1 (FFA1) Fluorescent Tracer. Journal of Medicinal Chemistry, 2016, 59, 4849-4858.	2.9	40
59	Dynamic Regulation of Quaternary Organization of the M1 Muscarinic Receptor by Subtype-selective Antagonist Drugs. Journal of Biological Chemistry, 2016, 291, 13132-13146.	1.6	37
60	Non-Acidic Free Fatty Acid Receptor 4 Agonists with Antidiabetic Activity. Journal of Medicinal Chemistry, 2016, 59, 8868-8878.	2.9	81
61	Targeted Elimination of G Proteins and Arrestins Defines Their Specific Contributions to Both Intensity and Duration of G Protein-coupled Receptor Signaling. Journal of Biological Chemistry, 2016, 291, 27147-27159.	1.6	143
62	Ligands at the Free Fatty Acid Receptors 2/3 (GPR43/GPR41). Handbook of Experimental Pharmacology, 2016, 236, 17-32.	0.9	27
63	A Molecular Mechanism for Sequential Activation of a G Protein-Coupled Receptor. Cell Chemical Biology, 2016, 23, 392-403.	2.5	30
64	Î²-Arrestin biosensors reveal a rapid, receptor-dependent activation/deactivation cycle. Nature, 2016, 531, 661-664.	13.7	190
65	Distinct Phosphorylation Clusters Determine the Signaling Outcome of Free Fatty Acid Receptor 4/G Proteinâ€“Coupled Receptor 120. Molecular Pharmacology, 2016, 89, 505-520.	1.0	53
66	Discovery of a Potent Free Fatty Acid 1 Receptor Agonist with Low Lipophilicity, Low Polar Surface Area, and Robust in Vivo Efficacy. Journal of Medicinal Chemistry, 2016, 59, 2841-2846.	2.9	20
67	Allosteric signaling through an mGlu2 and 5-HT _{2A} heteromeric receptor complex and its potential contribution to schizophrenia. Science Signaling, 2016, 9, ra5.	1.6	91
68	G-Protein-Coupled Receptor 35 Mediates Human Saphenous Vein Vascular Smooth Muscle Cell Migration and Endothelial Cell Proliferation. Journal of Vascular Research, 2015, 52, 383-395.	0.6	23
69	The First 50 Years of Molecular Pharmacology. Molecular Pharmacology, 2015, 88, 139-140.	1.0	4
70	The Molecular Basis of Oligomeric Organization of the Human M₃ Muscarinic Acetylcholine Receptor. Molecular Pharmacology, 2015, 87, 936-953.	1.0	20
71	The experimental power of FR900359 to study Gq-regulated biological processes. Nature Communications, 2015, 6, 10156.	5.8	282
72	G protein-coupled receptor 35: an emerging target in inflammatory and cardiovascular disease. Frontiers in Pharmacology, 2015, 6, 41.	1.6	70

#	Article	IF	Citations
73	Activity of dietary fatty acids on FFA1 and FFA4 and characterisation of pinolenic acid as a dual FFA1/FFA4 agonist with potential effect against metabolic diseases. British Journal of Nutrition, 2015, 113, 1677-1688.	1.2	93
74	Analysis of Human Dopamine D3 Receptor Quaternary Structure. Journal of Biological Chemistry, 2015, 290, 15146-15162.	1.6	23
75	Regulation of Oligomeric Organization of the Serotonin 5-Hydroxytryptamine 2C (5-HT2C) Receptor Observed by Spatial Intensity Distribution Analysis. Journal of Biological Chemistry, 2015, 290, 12844-12857.	1.6	55
76	Distinct Agonist Regulation of Muscarinic Acetylcholine M2-M3 Heteromers and Their Corresponding Homomers. Journal of Biological Chemistry, 2015, 290, 14785-14796.	1.6	9
77	Approaches to Characterize and Quantify Oligomerization of GPCRs. Methods in Molecular Biology, 2015, 1335, 95-105.	0.4	6
78	Defining the Functional Equivalence of Wild-Type and Chemically Engineered G Protein-Coupled Receptors. Neuromethods, 2015, , 1-28.	0.2	2
79	Complex Pharmacology of Novel Allosteric Free Fatty Acid 3 Receptor Ligands. Molecular Pharmacology, 2014, 86, 200-210.	1.0	58
80	Indomethacin Treatment Prevents High Fat Diet-induced Obesity and Insulin Resistance but Not Glucose Intolerance in C57BL/6J Mice. Journal of Biological Chemistry, 2014, 289, 16032-16045.	1.6	33
81	Angiotensin-(1â€“7) and angiotensin-(1â€“9): function in cardiac and vascular remodelling. Clinical Science, 2014, 126, 815-827.	1.8	114
82	Roundabout 1 exists predominantly as a basal dimeric complex and this is unaffected by binding of the ligand Slit2. Biochemical Journal, 2014, 461, 61-73.	1.7	30
83	G-protein-coupled receptors for free fatty acids: nutritional and therapeutic targets. British Journal of Nutrition, 2014, 111, S3-S7.	1.2	35
84	The Molecular Basis of Ligand Interaction at Free Fatty Acid Receptor 4 (FFA4/GPR120). Journal of Biological Chemistry, 2014, 289, 20345-20358.	1.6	60
85	The Antiallergic Mast Cell Stabilizers Lodoxamide and Bufrolin as the First High and Equipotent Agonists of Human and Rat GPR35. Molecular Pharmacology, 2014, 85, 91-104.	1.0	53
86	Treatment of Type 2 Diabetes by Free Fatty Acid Receptor Agonists. Frontiers in Endocrinology, 2014, 5, 137.	1.5	80
87	Concomitant Action of Structural Elements and Receptor Phosphorylation Determines Arrestin-3 Interaction with the Free Fatty Acid Receptor FFA4. Journal of Biological Chemistry, 2014, 289, 18451-18465.	1.6	57
88	G Proteinâ€“Coupled Receptor Oligomerization Revisited: Functional and Pharmacological Perspectives. Pharmacological Reviews, 2014, 66, 413-434.	7.1	497
89	Structural and biophysical characterisation of G protein-coupled receptor ligand binding using resonance energy transfer and fluorescent labelling techniques. Biochimica Et Biophysica Acta - Biomembranes, 2014, 1838, 3-14.	1.4	29
90	Profiling of transcriptional and epigenetic changes during directed endothelial differentiation of human embryonic stem cells identifies FOXA2 as a marker of early mesoderm commitment. Stem Cell Research and Therapy, 2013, 4, 36.	2.4	13

#	Article	IF	Citations
91	The Prevalence, Maintenance, and Relevance of G Proteinâ€“Coupled Receptor Oligomerization. Molecular Pharmacology, 2013, 84, 158-169.	1.0	95
92	Discovery of a Potent and Selective Free Fatty Acid Receptor 1 Agonist with Low Lipophilicity and High Oral Bioavailability. Journal of Medicinal Chemistry, 2013, 56, 982-992.	2.9	52
93	Defining the Molecular Basis for the First Potent and Selective Orthosteric Agonists of the FFA2 Free Fatty Acid Receptor. Journal of Biological Chemistry, 2013, 288, 17296-17312.	1.6	99
94	High-Throughput Identification and Characterization of Novel, Species-selective GPR35 Agonists. Journal of Pharmacology and Experimental Therapeutics, 2013, 344, 568-578.	1.3	32
95	MicroRNA regulation of endothelial homeostasis and commitmentâ€”implications for vascular regeneration strategies using stem cell therapies. Free Radical Biology and Medicine, 2013, 64, 52-60.	1.3	15
96	GPCR Oligomerization and Receptor Trafficking. Methods in Enzymology, 2013, 521, 69-90.	0.4	20
97	Regulation of cardiovascular remodeling by the counter-regulatory axis of the reninâ€“angiotensin system. Future Cardiology, 2013, 9, 23-38.	0.5	17
98	Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes. ACS Medicinal Chemistry Letters, 2013, 4, 441-445.	1.3	58
99	The Pharmacology of TUG-891, a Potent and Selective Agonist of the Free Fatty Acid Receptor 4 (FFA4/GPR120), Demonstrates Both Potential Opportunity and Possible Challenges to Therapeutic Agonism. Molecular Pharmacology, 2013, 84, 710-725.	1.0	172
100	Minireview: The Effects of Species Ortholog and SNP Variation on Receptors for Free Fatty Acids. Molecular Endocrinology, 2013, 27, 1177-1187.	3.7	28
101	The muscarinic M3 acetylcholine receptor exists as two differently sized complexes at the plasma membrane. Biochemical Journal, 2013, 452, 303-312.	1.7	72
102	The Therapeutic Potential of Allosteric Ligands for Free Fatty Acid Sensitive GPCRs. Current Topics in Medicinal Chemistry, 2013, 13, 14-25.	1.0	26
103	Differences in the Signaling Pathways of Î±1A- and Î±1B-Adrenoceptors Are Related to Different Endosomal Targeting. PLoS ONE, 2013, 8, e64996.	1.1	15
104	Staphylococcus aureusStaphopain A inhibits CXCR2-dependent neutrophil activation and chemotaxis. EMBO Journal, 2012, 31, 3607-3619.	3.5	88
105	Eukaryotic Translation Initiation Factor 3, Subunit a, Regulates the Extracellular Signal-Regulated Kinase Pathway. Molecular and Cellular Biology, 2012, 32, 88-95.	1.1	33
106	Intramolecular Fluorescence Resonance Energy Transfer (FRET) Sensors of the Orexin OX1 and OX2 Receptors Identify Slow Kinetics of Agonist Activation. Journal of Biological Chemistry, 2012, 287, 14937-14949.	1.6	21
107	Functional Homomers and Heteromers of Dopamine D2L and D3 Receptors Co-exist at the Cell Surface. Journal of Biological Chemistry, 2012, 287, 8864-8878.	1.6	41
108	Identification of Three Residues Essential for 5-Hydroxytryptamine 2A-Metabotropic Glutamate 2 (5-HT2AÂ·mGlu2) Receptor Heteromerization and Its Psychoactive Behavioral Function. Journal of Biological Chemistry, 2012, 287, 44301-44319.	1.6	122

#	Article	IF	Citations
109	Novel Role for Proteinase-activated Receptor 2 (PAR2) in Membrane Trafficking of Proteinase-activated Receptor 4 (PAR4). Journal of Biological Chemistry, 2012, 287, 16656-16669.	1.6	38
110	The Other Side of Opioid Receptor Signalling: Regulation by Protein-Protein Interaction. Current Drug Targets, 2012, 13, 80-102.	1.0	36
111	Chemically engineering ligand selectivity at the free fatty acid receptor 2 based on pharmacological variation between species orthologs. FASEB Journal, 2012, 26, 4951-4965.	0.2	75
112	Extracellular Ionic Locks Determine Variation in Constitutive Activity and Ligand Potency between Species Orthologs of the Free Fatty Acid Receptors FFA2 and FFA3. Journal of Biological Chemistry, 2012, 287, 41195-41209.	1.6	116
113	Antagonists of GPR35 Display High Species Ortholog Selectivity and Varying Modes of Action. Journal of Pharmacology and Experimental Therapeutics, 2012, 343, 683-695.	1.3	40
114	Discovery of a Potent and Selective GPR120 Agonist. Journal of Medicinal Chemistry, 2012, 55, 4511-4515.	2.9	145
115	Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonists: Mesylpropoxy Appendage Lowers Lipophilicity and Improves ADME Properties. Journal of Medicinal Chemistry, 2012, 55, 6624-6628.	2.9	50
116	Mechanism and Function of Drosophila capa GPCR: A Desiccation Stress-Responsive Receptor with Functional Homology to Human NeuromedinU Receptor. PLoS ONE, 2012, 7, e29897.	1.1	98
117	Role of MicroRNAs 99b, 181a, and 181b in the Differentiation of Human Embryonic Stem Cells to Vascular Endothelial Cells. Stem Cells, 2012, 30, 643-654.	1.4	92
118	The Role of miRNA in Stem Cell Pluripotency and Commitment to the Vascular Endothelial Lineage. Microcirculation, 2012, 19, 196-207.	1.0	7
119	Applying label-free dynamic mass redistribution technology to frame signaling of G proteinâ€“coupled receptors noninvasively in living cells. Nature Protocols, 2011, 6, 1748-1760.	5.5	154
120	Experimental Challenges to Targeting Poorly Characterized GPCRs: Uncovering the Therapeutic Potential for Free Fatty Acid Receptors. Advances in Pharmacology, 2011, 62, 175-218.	1.2	47
121	The sphingosine-1-phosphate receptor-1 antagonist, W146, causes early and short-lasting peripheral blood lymphopenia in mice. International Immunopharmacology, 2011, 11, 1773-1779.	1.7	64
122	When simple agonism is not enough: Emerging modalities of GPCR ligands. Molecular and Cellular Endocrinology, 2011, 331, 241-247.	1.6	57
123	Orthologue selectivity and ligand bias: translating the pharmacology of GPR35. Trends in Pharmacological Sciences, 2011, 32, 317-325.	4.0	54
124	The orexin OX1 receptor exists predominantly as a homodimer in the basal state: potential regulation of receptor organization by both agonist and antagonist ligands. Biochemical Journal, 2011, 439, 171-183.	1.7	31
125	Agonist activation of the G proteinâ€coupled receptor GPR35 involves transmembrane domain III and is transduced via Gî±₁₃ and î²â€arrestinâ€2. British Journal of Pharmacology, 2011, 162, 733-748.	2.7	59
126	Ligandâ€induced internalization of the orexin OX₁ and cannabinoid CB₁ receptors assessed via Nâ€terminal SNAP and CLIPâ€tagging. British Journal of Pharmacology, 2011, 162, 1439-1452.	2.7	34

#	Article	IF	Citations
127	Angiotensin1â€9 antagonises proâ€hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor. Journal of Physiology, 2011, 589, 939-951.	1.3	84
128	G proteinâ€“coupled receptor modulation with pepducins: moving closer to the clinic. Annals of the New York Academy of Sciences, 2011, 1226, 34-49.	1.8	39
129	MicroRNAs regulating cell pluripotency and vascular differentiation. Vascular Pharmacology, 2011, 55, 69-78.	1.0	14
130	Extracellular Loop 2 of the Free Fatty Acid Receptor 2 Mediates Allosterism of a Phenylacetamide Ago-Allosteric Modulator. Molecular Pharmacology, 2011, 80, 163-173.	1.0	78
131	Using the Flp-Inâ„¢ T-Rexâ„¢ System to Regulate GPCR Expression. Methods in Molecular Biology, 2011, 746, 21-37.	0.4	56
132	Real-time monitoring of redox changes in the mammalian endoplasmic reticulum. Journal of Cell Science, 2011, 124, 2349-2356.	1.2	91
133	Heteromultimerization of Cannabinoid CB1 Receptor and Orexin OX1 Receptor Generates a Unique Complex in Which Both Protomers Are Regulated by Orexin A. Journal of Biological Chemistry, 2011, 286, 37414-37428.	1.6	81
134	Selective Orthosteric Free Fatty Acid Receptor 2 (FFA2) Agonists. Journal of Biological Chemistry, 2011, 286, 10628-10640.	1.6	101
135	Developing Chemical Genetic Approaches to Explore G Protein-Coupled Receptor Function: Validation of the Use of a Receptor Activated Solely by Synthetic Ligand (RASSL). Molecular Pharmacology, 2011, 80, 1033-1046.	1.0	56
136	Novel mutation in the AVPR2 gene in a Danish male with nephrogenic diabetes insipidus caused by ER retention and subsequent lysosomal degradation of the mutant receptor. CKJ: Clinical Kidney Journal, 2011, 4, 158-163.	1.4	9
137	Novel Assay Technologies for the Discovery of G Protein-Coupled Receptor Drugs. Neuromethods, 2011, , 231-253.	0.2	1
138	Identification of novel species-selective agonists of the G-protein-coupled receptor GPR35 that promote recruitment of Î²-arrestin-2 and activate GÎ±13. Biochemical Journal, 2010, 432, 451-459.	1.7	91
139	Erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) blocks differentiation and maintains the expression of pluripotency markers in human embryonic stem cells. Biochemical Journal, 2010, 432, 575-599.	1.7	6
140	Identification and characterization of small-molecule ligands that maintain pluripotency of human embryonic stem cells. Biochemical Society Transactions, 2010, 38, 1058-1061.	1.6	14
141	Applications of fluorescence and bioluminescence resonance energy transfer to drug discovery at G protein coupled receptors. Analytical and Bioanalytical Chemistry, 2010, 398, 167-180.	1.9	33
142	Deconvolution of complex G proteinâ€“coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nature Biotechnology, 2010, 28, 943-949.	9.4	246
143	GPCR-G protein fusions: Use in functional dimerization analysis. , 2010, , 53-66.		1
144	Role of metabotropic glutamate receptors in CNS disorders. , 2010, , 321-379.		9

#	Article	IF	Citations
145	High-content screening of feeder-free human embryonic stem cells to identify pro-survival small molecules. Biochemical Journal, 2010, 432, 21-35.	1.7	35
146	Ligand Regulation of the Quaternary Organization of Cell Surface M3 Muscarinic Acetylcholine Receptors Analyzed by Fluorescence Resonance Energy Transfer (FRET) Imaging and Homogeneous Time-resolved FRET. Journal of Biological Chemistry, 2010, 285, 23318-23330.	1.6	52
147	Heterodimerisation of G protein-coupled receptors: implications for drug design and ligand screening. Expert Opinion on Drug Discovery, 2010, 5, 461-474.	2.5	12
148	GPCR-OKB: the G Protein Coupled Receptor Oligomer Knowledge Base. Bioinformatics, 2010, 26, 1804-1805.	1.8	74
149	Constitutive Activity of GPR40/FFA1. Methods in Enzymology, 2010, 484, 569-590.	0.4	7
150	Derivation of Endothelial Cells From Human Embryonic Stem Cells by Directed Differentiation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1389-1397.	1.1	147
151	Lentivirus-mediated Reprogramming of Somatic Cells in the Absence of Transgenic Transcription Factors. Molecular Therapy, 2010, 18, 2139-2145.	3.7	32
152	Allostery at G Protein-Coupled Receptor Homo- and Heteromers: Uncharted Pharmacological Landscapes. Pharmacological Reviews, 2010, 62, 701-725.	7.1	246
153	The role of dimerisation in the cellular trafficking of G-protein-coupled receptors. Current Opinion in Pharmacology, 2010, 10, 23-29.	1.7	114
154	Inferring Signaling Pathway Topologies from Multiple Perturbation Measurements of Specific Biochemical Species. Science Signaling, 2010, 3, ra20.	1.6	101
155	Opioid Regulation of Mu Receptor Internalisation: Relevance to the Development of Tolerance and Dependence. CNS and Neurological Disorders - Drug Targets, 2010, 9, 616-626.	0.8	11
156	Evidence for Distinct Antagonist-Revealed Functional States of 5-Hydroxytryptamine_{2A}Receptor Homodimers. Molecular Pharmacology, 2009, 75, 1380-1391.	1.0	60
157	Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12195-12200.	3.3	87
158	The Action and Mode of Binding of Thiazolidinedione Ligands at Free Fatty Acid Receptor 1. Journal of Biological Chemistry, 2009, 284, 17527-17539.	1.6	74
159	Localization of the succinate receptor in the distal nephron and its signaling in polarized MDCK cells. Kidney International, 2009, 76, 1258-1267.	2.6	91
160	Growth Hormone Secretagogues and Growth Hormone Releasing Peptides Act As Orthosteric Super-Agonists but Not Allosteric Regulators for Activation of the G Protein Gî±_{o1}by the Ghrelin Receptor. Molecular Pharmacology, 2009, 76, 802-811.	1.0	35
161	Building a new conceptual framework for receptor heteromers. Nature Chemical Biology, 2009, 5, 131-134.	3.9	349
162	G proteinâ€coupled receptor heteroâ€dimerization: contribution to pharmacology and function. British Journal of Pharmacology, 2009, 158, 5-14.	2.7	303

#	Article	IF	Citations
163	Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and FFA3. British Journal of Pharmacology, 2009, 158, 146-153.	2.7	59
164	Selectivity and functional consequences of interactions of family A G proteinâ€coupled receptors with neurochondrin and periplakin. Journal of Neurochemistry, 2009, 109, 182-192.	2.1	19
165	Cannabinoid Receptor Type 1 Protects against Age- Related Osteoporosis by Regulating Osteoblast and Adipocyte Differentiation in Marrow Stromal Cells. Cell Metabolism, 2009, 10, 139-147.	7.2	151
166	17-P003 Discovery of small molecules to control human embryonic stem cell fate. Mechanisms of Development, 2009, 126, S271-S272.	1.7	1
167	Chapter 10 Heteroâ€Oligomerization of Chemokine Receptors. Methods in Enzymology, 2009, 461, 207-225.	0.4	6
168	Cell surface delivery and structural re-organization by pharmacological chaperones of an oligomerization-defective Î±1b-adrenoceptor mutant demonstrates membrane targeting of GPCR oligomers. Biochemical Journal, 2009, 417, 161-172.	1.7	36
169	Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature, 2008, 452, 93-97.	13.7	739
170	Isolation and characterization of a novel human RGS mutant displaying gain-of-function activity. Cellular Signalling, 2008, 20, 323-336.	1.7	4
171	Morphine Desensitization, Internalization, and Down-Regulation of the Î¼ Opioid Receptor Is Facilitated by Serotonin 5-Hydroxytryptamine_{2A} Receptor Coactivation. Molecular Pharmacology, 2008, 74, 1278-1291.	1.0	47
172	International Union of Pharmacology. LXXI. Free Fatty Acid Receptors FFA1, -2, and -3: Pharmacology and Pathophysiological Functions. Pharmacological Reviews, 2008, 60, 405-417.	7.1	293
173	Mutations of Î²-arrestin 2 that limit self-association also interfere with interactions with the Î²2-adrenoceptor and the ERK1/2 MAPKs: implications for Î²2-adrenoceptor signalling via the ERK1/2 MAPKs. Biochemical Journal, 2008, 413, 51-60.	1.7	40
174	Constitutive Activity of the Cannabinoid CB1 Receptor Regulates the Function of Co-expressed Mu Opioid Receptors. Journal of Biological Chemistry, 2008, 283, 11424-11434.	1.6	78
175	Multiple Roles for the C-terminal Tail of the Chemokine Scavenger D6. Journal of Biological Chemistry, 2008, 283, 7972-7982.	1.6	61
176	Conserved Polar Residues in Transmembrane Domains V, VI, and VII of Free Fatty Acid Receptor 2 and Free Fatty Acid Receptor 3 Are Required for the Binding and Function of Short Chain Fatty Acids. Journal of Biological Chemistry, 2008, 283, 32913-32924.	1.6	96
177	Antibodies that identify only the active conformation of G_ifamily G protein Î± subunits. FASEB Journal, 2008, 22, 1924-1932.	0.2	20
178	Autoimmune Disease-Associated Histamine Receptor H1 Alleles Exhibit Differential Protein Trafficking and Cell Surface Expression. Journal of Immunology, 2008, 180, 7471-7479.	0.4	13
179	G Protein Coupling and Ligand Selectivity of the D_{2L}and D₃Dopamine Receptors. Journal of Pharmacology and Experimental Therapeutics, 2008, 325, 319-330.	1.3	57
180	CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2â€"DOP receptor heterodimer. Biochemical Journal, 2008, 412, 245-256.	1.7	76

#	Article	IF	Citations
181	Polymorphisms in murine histamine receptor H1 leading to differential cell surface expression influence autoimmune disease progression. FASEB Journal, 2008, 22, 667.2.	0.2	0
182	Uncovering the Pharmacology of the G Protein-Coupled Receptor GPR40: High Apparent Constitutive Activity in Guanosine 5â€²-O-(3-[35S]thio)triphosphate Binding Studies Reflects Binding of an Endogenous Agonist. Molecular Pharmacology, 2007, 71, 994-1005.	1.0	77
183	International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the Recognition and Nomenclature of G Protein-Coupled Receptor Heteromultimers. Pharmacological Reviews, 2007, 59, 5-13.	7.1	274
184	The Î±1b-Adrenoceptor Exists as a Higher-Order Oligomer: Effective Oligomerization Is Required for Receptor Maturation, Surface Delivery, and Function. Molecular Pharmacology, 2007, 71, 1015-1029.	1.0	154
185	Protean Agonism at the Dopamine D2 Receptor: (S)-3-(3-Hydroxyphenyl)-N-propylpiperidine Is an Agonist for Activation of Go1 but an Antagonist/Inverse Agonist for Gi1,Gi2, and Gi3. Molecular Pharmacology, 2007, 71, 1349-1359.	1.0	63
186	Mapping binding sites for the PDE4D5 cAMP-specific phosphodiesterase to the N- and C-domains of Î²-arrestin using spot-immobilized peptide arrays. Biochemical Journal, 2007, 404, 71-80.	1.7	88
187	Allosteric modulation of heterodimeric G-protein-coupled receptors. Trends in Pharmacological Sciences, 2007, 28, 615-620.	4.0	162
188	G protein-coupled receptor dimerisation: Molecular basis and relevance to function. Biochimica Et Biophysica Acta - Biomembranes, 2007, 1768, 825-835.	1.4	149
189	Novel pharmacological applications of G-protein-coupled receptorâ€“G protein fusions. Current Opinion in Pharmacology, 2007, 7, 521-526.	1.7	23
190	Capillary Electrophoresis Assay for G Protein-Coupled Receptor-Mediated GTPase Activity. Analytical Chemistry, 2007, 79, 1158-1163.	3.2	5
191	BRET analysis of GPCR oligomerization: newer does not mean better. Nature Methods, 2007, 4, 3-4.	9.0	126
192	Requirements and ontology for a G protein-coupled receptor oligomerization knowledge base. BMC Bioinformatics, 2007, 8, 177.	1.2	42
193	Agonist occupancy of a single monomeric element is sufficient to cause internalization of the dimeric Î²2-adrenoceptor. Cellular Signalling, 2007, 19, 1928-1938.	1.7	38
194	Action of Pasteurella multocida toxin on GÎ±q is persistent and independent of interaction with G-protein-coupled receptors. Cellular Signalling, 2007, 19, 2174-2182.	1.7	21
195	Histamine receptor H1 is required for TCR-mediated p38 MAPK activation and optimal IFN-Î³ production in mice. Journal of Clinical Investigation, 2007, 117, 3507-3518.	3.9	76
196	Carvedilol-induced antagonism of angiotensin II: a matter of Î±1-adrenoceptor blockade. Journal of Hypertension, 2006, 24, 1355-1363.	0.3	20
197	Heterotrimeric G-proteins: a short history. British Journal of Pharmacology, 2006, 147, S46-S55.	2.7	347
198	Oligomeric structure of the Î±1b-adrenoceptor: Comparisons with rhodopsin. Vision Research, 2006, 46, 4434-4441.	0.7	9

#	Article	IF	Citations
199	Functional interactions between the Î±1b-adrenoceptor and GÎ±11 are compromised by de-palmitoylation of the G protein but not of the receptor. Cellular Signalling, 2006, 18, 1244-1251.	1.7	9
200	G protein-coupled receptors for free fatty acids. Cellular Signalling, 2006, 18, 1360-1365.	1.7	65
201	G-protein-coupled receptor heterodimers: pharmacology, function and relevance to drug discovery. Drug Discovery Today, 2006, 11, 541-549.	3.2	124
202	The chemokine receptor CCX-CKR mediates effective scavenging of CCL19in vitro. European Journal of Immunology, 2006, 36, 1904-1916.	1.6	127
203	Interactions between the Mas-Related Receptors MrgD and MrgE Alter Signalling and Trafficking of MrgD. Molecular Pharmacology, 2006, 69, 479-491.	1.0	74
204	Presynaptic Control of Striatal Glutamatergic Neurotransmission by Adenosine A1-A2A Receptor Heteromers. Journal of Neuroscience, 2006, 26, 2080-2087.	1.7	553
205	Orexin-1 Receptor-Cannabinoid CB1 Receptor Heterodimerization Results in Both Ligand-dependent and -independent Coordinated Alterations of Receptor Localization and Function. Journal of Biological Chemistry, 2006, 281, 38812-38824.	1.6	197
206	Up-regulation of the Angiotensin II Type 1 Receptor by the MAS Proto-oncogene Is Due to Constitutive Activation of Gq/G11 by MAS. Journal of Biological Chemistry, 2006, 281, 16757-16767.	1.6	77
207	Interaction of Neurochondrin with the Melanin-concentrating Hormone Receptor 1 Interferes with G Protein-coupled Signal Transduction but Not Agonist-mediated Internalization. Journal of Biological Chemistry, 2006, 281, 32496-32507.	1.6	30
208	Î¼-Î´ Opioid Receptor Functional Interaction: Insight Using Receptor-G Protein Fusions. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 683-690.	1.3	23
209	Activation of an Î±2A-adrenoceptorâ€“GÎ±o1 fusion protein dynamically regulates the palmitoylation status of the G protein but not of the receptor. Biochemical Journal, 2005, 385, 197-206.	1.7	15
210	The sustainability of interactions between the orexin-1 receptor and Î²-arrestin-2 is defined by a single C-terminal cluster of hydroxy amino acids and modulates the kinetics of ERK MAPK regulation. Biochemical Journal, 2005, 387, 573-584.	1.7	72
211	The Specificity and Molecular Basis of Î±₁-Adrenoceptor and CXCR Chemokine Receptor Dimerization. Journal of Molecular Neuroscience, 2005, 26, 161-168.	1.1	30
212	Opioid Receptors and Their Interacting Proteins. NeuroMolecular Medicine, 2005, 7, 051-060.	1.8	36
213	Methods to monitor the quaternary structure of G protein-coupled receptors. FEBS Journal, 2005, 272, 2914-2925.	2.2	203
214	The quaternary structure of G protein-coupled receptors. FEBS Journal, 2005, 272, 2913-2913.	2.2	1
215	A Highly Conserved Glycine within Linker I and the Extreme C Terminus of G Protein Î± Subunits Interact Cooperatively in Switching G Protein-Coupled Receptor-to-Effector Specificity. Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 78-87.	1.3	58
216	Î²-Arrestin-Dependent Spontaneous Î±1a-Adrenoceptor Endocytosis Causes Intracellular Transportation of Î±-Blockers via Recycling Compartments. Molecular Pharmacology, 2005, 67, 992-1004.	1.0	42

#	Article	IF	Citations
217	Dominant Portion of Thyrotropin-Releasing Hormone Receptor Is Excluded from Lipid Domains. Detergent-Resistant and Detergent-Sensitive Pools of TRH Receptor and GqÎ±/G11Î± Protein. Journal of Biochemistry, 2005, 138, 111-125.	0.9	17
218	A Key Serine for the GTPase-Activating Protein Function of Regulator of G Protein Signaling Proteins Is Not a General Target for 14-3-3 Interactions. Molecular Pharmacology, 2005, 68, 1821-1830.	1.0	18
219	Periplakin Interferes with G Protein Activation by the Melanin-concentrating Hormone Receptor-1 by Binding to the Proximal Segment of the Receptor C-terminal Tail. Journal of Biological Chemistry, 2005, 280, 8208-8220.	1.6	35
220	Î²-Arrestin 2-Dependent Angiotensin II Type 1A Receptor-Mediated Pathway of Chemotaxis. Molecular Pharmacology, 2005, 67, 1229-1236.	1.0	115
221	G-Proteinâ€“Coupled Receptor Mas Is a Physiological Antagonist of the Angiotensin II Type 1 Receptor. Circulation, 2005, 111, 1806-1813.	1.6	346
222	Î²-Arrestin 1 and GÎ±q/11 Coordinately Activate RhoA and Stress Fiber Formation following Receptor Stimulation. Journal of Biological Chemistry, 2005, 280, 8041-8050.	1.6	180
223	The CXCR1 and CXCR2 Receptors Form Constitutive Homo- and Heterodimers Selectively and with Equal Apparent Affinities. Journal of Biological Chemistry, 2005, 280, 28663-28674.	1.6	113
224	Functional Complementation and the Analysis of Opioid Receptor Homodimerization. Molecular Pharmacology, 2005, 68, 905-915.	1.0	40
225	Functional Complementation and the Analysis of GPCR Dimerization. Contemporary Clinical Neuroscience, 2005, , 267-285.	0.3	1
226	Analysis of endogenous S1P and LPA receptor expression in CHO-K1 cells. Gene, 2005, 350, 59-63.	1.0	20
227	Techniques: Promiscuous GÎ± proteins in basic research and drug discovery. Trends in Pharmacological Sciences, 2005, 26, 595-602.	4.0	125
228	Domain Swapping in the Human Histamine H1 Receptor. Journal of Pharmacology and Experimental Therapeutics, 2004, 311, 131-138.	1.3	77
229	Multiple Interactions between Transmembrane Helices Generate the Oligomeric Î±1b-Adrenoceptor. Molecular Pharmacology, 2004, 66, 1123-1137.	1.0	95
230	Identification of a Novel Site within G Protein Î± Subunits Important for Specificity of Receptor-G Protein Interaction. Molecular Pharmacology, 2004, 66, 250-259.	1.0	50
231	High-Affinity Interactions between Human Î±1A-Adrenoceptor C-Terminal Splice Variants Produce Homo- and Heterodimers but Do Not Generate the Î±1L-Adrenoceptor. Molecular Pharmacology, 2004, 66, 228-239.	1.0	65
232	Allosteric modulation and constitutive activity of fusion proteins between the adenosine A1 receptor and different 351Cys-mutated Gi Î±-subunits. European Journal of Pharmacology, 2004, 499, 91-98.	1.7	5
233	Applications of bioluminescence- and fluorescence resonance energy transfer to drug discovery at G protein-coupled receptors. European Journal of Pharmaceutical Sciences, 2004, 21, 397-405.	1.9	119
234	Long-term agonist stimulation of IP prostanoid receptor depletes the cognate GsÎ± protein in membrane domains but does not change the receptor level. Biochimica Et Biophysica Acta - Molecular Cell Research, 2004, 1691, 51-65.	1.9	14

#	Article	IF	Citations
235	Monitoring Receptor Dimerisation. Medicinal Chemistry Research, 2004, 13, 18-24.	1.1	0
236	A single amino acid determines preference between phospholipids and reveals length restriction for activation of the S1P4 receptor. BMC Biochemistry, 2004, 5, 12.	4.4	20
237	Selectivity in the oligomerisation of G protein-coupled receptors. Seminars in Cell and Developmental Biology, 2004, 15, 263-268.	2.3	8
238	G protein-coupled receptors: oligomerisation and association with accessory proteins. Seminars in Cell and Developmental Biology, 2004, 15, 261.	2.3	2
239	Identification and Quantitation of G-Protein Î±-Subunits. , 2004, 259, 207-224.		1
240	G Protein-Coupled Receptor Dimerization: Function and Ligand Pharmacology. Molecular Pharmacology, 2004, 66, 1-7.	1.0	366
241	High-content assays for ligand regulation of G-protein-coupled receptors. Drug Discovery Today, 2003, 8, 579-585.	3.2	72
242	Î˜â€Opioid receptors exhibit high efficiency when activating trimeric G proteins in membrane domains. Journal of Neurochemistry, 2003, 85, 34-49.	2.1	19
243	Concerted stimulation and deactivation of pertussis toxin-sensitive Gâ€ƒproteins by chimeric Gâ€ƒprotein-coupled receptor-regulator of Gâ€ƒprotein signaling 4 fusion proteins: analysis of the contribution of palmitoylated cysteine residues to the GAP activity o. Journal of Neurochemistry, 2003, 85, 1289-1298.	2.1	15
244	GPCR dimerisation. Life Sciences, 2003, 74, 181-188.	2.0	80
245	Constitutive Activity and Inverse Agonists of G Protein-Coupled Receptors: a Current Perspective: TABLE 1. Molecular Pharmacology, 2003, 64, 1271-1276.	1.0	239
246	Novel approaches to enhance the detection of receptor constitutive activity and inverse agonists. International Congress Series, 2003, 1249, 15-25.	0.2	1
247	Principles: Extending the utility of [35S]GTPÎ³S binding assays. Trends in Pharmacological Sciences, 2003, 24, 87-90.	4.0	184
248	Palmitoylation Regulates Regulator of G-protein Signaling (RGS) 16 Function. Journal of Biological Chemistry, 2003, 278, 19309-19316.	1.6	46
249	Selective Interactions between Helix VIII of the Human Î¼-Opioid Receptors and the C Terminus of Periplakin Disrupt G Protein Activation. Journal of Biological Chemistry, 2003, 278, 33400-33407.	1.6	50
250	Palmitoylation Regulates Regulators of G-protein Signaling (RGS) 16 Function. Journal of Biological Chemistry, 2003, 278, 19301-19308.	1.6	69
251	Dimers of Class A G Protein-coupled Receptors Function via Agonist-mediated Trans-activation of Associated G Proteins. Journal of Biological Chemistry, 2003, 278, 42578-42587.	1.6	101
252	Ligand Specific Up-Regulation of a Renilla reniformis Luciferase-Tagged, Structurally Unstable Muscarinic M3 Chimeric G Protein-Coupled Receptor. Molecular Pharmacology, 2003, 64, 1474-1484.	1.0	13

#	Article	IF	Citations
253	Mechanism of Action of Gqto Inhibit GÎ²Î³ Modulation of CaV2.2 Calcium Channels: Probed by the Use of Receptor-GÎ± Tandems. Molecular Pharmacology, 2003, 63, 832-843.	1.0	16
254	CypHer 5: A Generic Approach for Measuring the Activation and Trafficking of G Protein-Coupled Receptors in Live Cells. Assay and Drug Development Technologies, 2003, 1, 251-259.	0.6	33
255	Src-mediated RGS16 Tyrosine Phosphorylation Promotes RGS16 Stability. Journal of Biological Chemistry, 2003, 278, 16107-16116.	1.6	42
256	The Dynamics of Formation and Action of the Ternary Complex Revealed in Living Cells Using a G-protein-gated K+ Channel as a Biosensor. Journal of Biological Chemistry, 2003, 278, 10851-10858.	1.6	38
257	Using Receptor-G-Protein Chimeras to Screen for Drugs. , 2003, , 619-621.		0
258	Effective Information Transfer from the Î±1b-Adrenoceptor to GÎ±11 Requires Both Î²/Î³ Interactions and an Aromatic Group Four Amino Acids from the C Terminus of the G Protein. Journal of Biological Chemistry, 2002, 277, 25707-25714.	1.6	32
259	Measurement of Agonist-Dependent and -Independent Signal Initiation of Î±1b-Adrenoceptor Mutants by Direct Analysis of Guanine Nucleotide Exchange on the G Protein GÎ±11. Journal of Pharmacology and Experimental Therapeutics, 2002, 302, 1080-1088.	1.3	29
260	Lymphocyte trafficking through the bloodâ€“brain barrier is dependent on endothelial cell heterotrimeric Gâ€protein signaling. FASEB Journal, 2002, 16, 1185-1194.	0.2	34
261	Enhanced Detection of Receptor Constitutive Activity in the Presence of Regulators of G Protein Signaling: Applications to the Detection and Analysis of Inverse Agonists and Low-Efficacy Partial Agonists. Molecular Pharmacology, 2002, 61, 1211-1221.	1.0	25
262	Construction and analysis of function of G protein-coupled receptor-G protein fusion proteins. Methods in Enzymology, 2002, 343, 260-273.	0.4	14
263	Generation and Analysis of Constitutively Active and Physically Destabilized Mutants of the Human Î²1-Adrenoceptor. Molecular Pharmacology, 2002, 62, 747-755.	1.0	20
264	The Use of Receptor G-Protein Fusion Proteins for the Study of Ligand Activity. Receptors and Channels, 2002, 8, 309-317.	1.1	6
265	Homo- and hetero-oligomeric interactions between G-protein-coupled receptors in living cells monitored by two variants of bioluminescence resonance energy transfer (BRET): hetero-oligomers between receptor subtypes form more efficiently than between less closely related sequences. Biochemical Journal, 2002, 365, 429-440.	1.7	197
266	Ligand Rescue of Constitutively Active Mutant Receptors. NeuroSignals, 2002, 11, 29-33.	0.5	16
267	Analysis of Protein Palmitoylation. , 2002, , 633-640.		0
268	Reciprocal mutations of highly conserved residues in transmembrane helices 2 and 7 of the Î±2A-adrenoceptor restore agonist activation of Gi1Î±. Cellular Signalling, 2002, 14, 139-144.	1.7	8
269	Engineering a V2 Vasopressin Receptor Agonist- and Regulator of G-Protein-Signaling-Sensitive G Protein. Analytical Biochemistry, 2002, 300, 212-220.	1.1	8
270	Agonists activate Gi1Î± or Gi2Î± fused to the human mu opioid receptor differently. Journal of Neurochemistry, 2002, 81, 1372-1382.	2.1	42

#	Article	IF	Citations
271	Expression of the Human Î²2-Adrenoceptor in NCB20 Cells Results in Agonist Activation of Adenylyl Cyclase and Agonist-Mediated Selective Down-Regulation of GsÎ±. Journal of Neurochemistry, 2002, 65, 545-553.	2.1	16
272	Regulation of the avidity of ternary complexes containing the human 5-HT1Areceptor by mutation of a receptor contact site on the interacting G protein Î± subunit. British Journal of Pharmacology, 2002, 137, 345-352.	2.7	5
273	Expression of gsÎ±, connexin-43, connexin-26, and EP1, 3, and 4 receptors in myometrium of prelabor singleton versus multiple gestations and the effects of mechanical stretch and steroids on gsÎ±. Journal of the Society for Gynecologic Investigation, 2002, 9, 299-307.	1.9	18
274	The Use of Receptor G-Protein Fusion Proteins for the Study of Ligand Activity. Receptors and Channels, 2002, 8, 309-317.	1.1	13
275	The use of receptor G-protein fusion proteins for the study of ligand activity. Receptors and Channels, 2002, 8, 309-17.	1.1	2
276	Proteinâ€“protein interactions at G-protein-coupled receptors. Trends in Pharmacological Sciences, 2001, 22, 513-518.	4.0	113
277	S 14506: novel receptor coupling at 5-HT1A receptors. Neuropharmacology, 2001, 40, 334-344.	2.0	24
278	The human Î´ opioid receptor activates Gi1Î± more efficiently than Go1Î±. Journal of Neurochemistry, 2001, 76, 1805-1813.	2.1	39
279	Visualizing differences in ligand-induced Î²-arrestin-GFP interactions and trafficking between three recently characterized Gâ€ƒprotein-coupled receptors. Journal of Neurochemistry, 2001, 77, 476-485.	2.1	70
280	Differential capacities of the RGS1, RGS16 and RGS-GAIP regulators of G protein signaling to enhance Î±2A-adrenoreceptor agonist-stimulated GTPase activity of Go1Î±. Journal of Neurochemistry, 2001, 78, 797-806.	2.1	29
281	Multiple pertussis toxin-sensitive G-proteins can couple receptors to GIRK channels in rat sympathetic neurons when expressed heterologously, but only native Gi-proteins do soin situ. European Journal of Neuroscience, 2001, 14, 283-292.	1.2	30
282	Detection of receptor ligands by monitoring selective stabilization of a Renilla luciferase-tagged, constitutively active mutant, G-protein-coupled receptor. British Journal of Pharmacology, 2001, 133, 315-323.	2.7	19
283	Monitoring Receptor Oligomerization Using Time-resolved Fluorescence Resonance Energy Transfer and Bioluminescence Resonance Energy Transfer. Journal of Biological Chemistry, 2001, 276, 14092-14099.	1.6	227
284	Coordinated Agonist Regulation of Receptor and G Protein Palmitoylation and Functional Rescue of Palmitoylation-deficient Mutants of the G Protein G11Î± following Fusion to the Î±1b-Adrenoreceptor. Journal of Biological Chemistry, 2001, 276, 35883-35890.	1.6	45
285	Analysis of the C-Terminal Tail of the Rat Thyrotropin-Releasing Hormone Receptor-1 in Interactions and Cointernalization with Î²-Arrestin 1-Green Fluorescent Protein. Molecular Pharmacology, 2001, 59, 375-385.	1.0	37
286	Chapter 24. Oligomerisation of G protein-coupled receptors. Annual Reports in Medicinal Chemistry, 2000, 35, 271-279.	0.5	5
287	Kinetic analysis of the internalization and recycling of [3H]TRH and C-terminal truncations of the long isoform of the rat thyrotropin-releasing hormone receptor-1. Biochemical Journal, 2000, 346, 711-718.	1.7	23
288	Kinetic analysis of the internalization and recycling of [3H]TRH and C-terminal truncations of the long isoform of the rat thyrotropin-releasing hormone receptor-1. Biochemical Journal, 2000, 346, 711.	1.7	5

#	Article	IF	Citations
289	Ligand regulation of green fluorescent protein-tagged forms of the human Î²1 - and Î²2 -adrenoceptors; comparisons with the unmodified receptors. British Journal of Pharmacology, 2000, 130, 1825-1832.	2.7	72
290	Resolution of Inverse Agonist-Induced Up-Regulation from Constitutive Activity of Mutants of the Î±1b-Adrenoceptor. Molecular Pharmacology, 2000, 58, 438-448.	1.0	30
291	Receptor for the Pain Modulatory Neuropeptides FF and AF Is an Orphan G Protein-coupled Receptor. Journal of Biological Chemistry, 2000, 275, 25965-25971.	1.6	233
292	The Regulator of G Protein Signaling RGS4 Selectively Enhances Î±2A-Adreoreceptor Stimulation of the GTPase Activity of Go1Î± and Gi2Î±. Journal of Biological Chemistry, 2000, 275, 23693-23699.	1.6	62
293	The G Protein Î± Subunit Has a Key Role in Determining the Specificity of Coupling to, but Not the Activation of, G Protein-gated Inwardly Rectifying K+ Channels. Journal of Biological Chemistry, 2000, 275, 921-929.	1.6	75
294	Insights into ligand pharmacology using receptorâ€“G-protein fusion proteins. Trends in Pharmacological Sciences, 2000, 21, 24-28.	4.0	109
295	Visualizing Differences in Ligand Regulation of Wild-Type and Constitutively Active Mutant Î²2-Adrenoceptor-Green Fluorescent Protein Fusion Proteins. Molecular Pharmacology, 1999, 56, 1182-1191.	1.0	36
296	Modulation of Relative Intrinsic Activity of Agonists at theAlpha-2A Adrenoceptor by Mutation of Residue 351 of G Protein Gi1Î±. Molecular Pharmacology, 1999, 55, 195-201.	1.0	34
297	Kinetics of Ternary Complex Formation with Fusion Proteins Composed of the A1-Adenosine Receptor and G Protein Î±-Subunits. Journal of Biological Chemistry, 1999, 274, 30571-30579.	1.6	46
298	The Dually Acylated NH2-terminal Domain of Gi1Î± Is Sufficient to Target a Green Fluorescent Protein Reporter to Caveolin-enriched Plasma Membrane Domains. Journal of Biological Chemistry, 1999, 274, 5843-5850.	1.6	93
299	Visualization of Agonist-induced Association and Trafficking of Green Fluorescent Protein-tagged Forms of Both Î²-Arrestin-1 and the Thyrotropin-releasing Hormone Receptor-1. Journal of Biological Chemistry, 1999, 274, 23263-23269.	1.6	41
300	Î²Î³ dimers derived from Goand Giproteins contribute different components of adrenergic inhibition of Ca2+channels in rat sympathetic neurones. Journal of Physiology, 1999, 518, 23-36.	1.3	57
301	Exploring the dynamics of regulation of G protein-coupled receptors using green fluorescent protein. British Journal of Pharmacology, 1999, 128, 501-510.	2.7	61
302	Chimaeric GÎ± proteins: their potential use in drug discovery. Trends in Pharmacological Sciences, 1999, 20, 118-124.	4.0	88
303	Functional analysis of a human A1adenosine receptor/green fluorescent protein/Gi1Î± fusion protein following stable expression in CHO cells. FEBS Letters, 1999, 462, 61-65.	1.3	17
304	An Asp79Asn mutation of the Î±2A-adrenoceptor interferes equally with agonist activation of individual GiÎ±-family G protein subtypes. FEBS Letters, 1999, 462, 459-463.	1.3	13
305	Thyrotropin-releasing hormone-induced depletion of Gq Î±/G11 Î± proteins from detergent-insensitive membrane domains. FEBS Letters, 1999, 464, 35-40.	1.3	21
306	Comparative Analysis of the Efficacy of A1Adenosine Receptor Activation of Gi/oÎ± G Proteins following Coexpression of Receptor and G Protein and Expression of A1Adenosine Receptorâ˜Gi/oÎ± Fusion Proteinsâ€. Biochemistry, 1999, 38, 2272-2278.	1.2	62

#	Article	IF	Citations
307	Internalisation of Wild type and Mutant Î±1B-Adrenergic Receptors. Biochemical Society Transactions, 1999, 27, A114-A114.	1.6	0
308	Visualization of distinct patterns of subcellular redistribution of the thyrotropin-releasing hormone receptor-1 and GqÎ± /G11Î± induced by agonist stimulation. Biochemical Journal, 1999, 340, 529-538.	1.7	36
309	Analysis of agonist function at fusion proteins between the IP prostanoid receptor and cognate, unnatural and chimaeric G-proteins. Biochemical Journal, 1999, 342, 457-463.	1.7	31
310	Diversity in the signaling and regulation of G protein-coupled receptors. Biochemical Society Transactions, 1999, 27, A24-A24.	1.6	0
311	Receptor-GFP Fusion Proteins; A study of Drug Effects on Receptor Internalisation, Trafficking and Expression. Biochemical Society Transactions, 1999, 27, A114-A114.	1.6	0
312	G protein activation and effector regulation by the human 5-HT1A receptor and the Î± subunit of Gi1 fusion proteins. Biochemical Society Transactions, 1999, 27, A114-A114.	1.6	0
313	Cell Cycle Regulation in Rat 1 Fibroblasts Expressing a Murine Delta Opioid Gi Linked Receptor. Biochemical Society Transactions, 1999, 27, A114-A114.	1.6	0
314	Construction and Analysis of Î±2A-Adrenoceptor Gi/GoÎ±-Subunit Fusion Proteins. Biochemical Society Transactions, 1999, 27, A115-A115.	1.6	0
315	Characterisation of Three Subtypes of Rat Thyrotropin Releasing Hormone Receptor. Biochemical Society Transactions, 1999, 27, A115-A115.	1.6	0
316	Activation and Desensitisation of the Thyrotropin-Releasing Hormone Receptor Visualised by Monitoring Cellular Redistribution of a Î²-arrestin-1-Green Fluorescent Protein Fusion Protein. Biochemical Society Transactions, 1999, 27, A118-A118.	1.6	0
317	Visualization of distinct patterns of subcellular redistribution of the thyrotropin-releasing hormone receptor-1 and GqÎ± /G11Î± induced by agonist stimulation. Biochemical Journal, 1999, 340, 529.	1.7	9
318	Analysis of agonist function at fusion proteins between the IP prostanoid receptor and cognate, unnatural and chimaeric G-proteins. Biochemical Journal, 1999, 342, 457.	1.7	14
319	Efficacy of inverse agonists in cells overexpressing a constitutively active Î² 2 -adrenoceptor and type II adenylyl cyclase. British Journal of Pharmacology, 1998, 123, 335-343.	2.7	21
320	Stimulation of p70S6 kinase phosphorylation by the A2A adenosine receptor in primary human endothelial cells and in CHO cells heterologously expressing the receptor. Drug Development Research, 1998, 45, 140-150.	1.4	1
321	G-proteins and G-protein subunits mediating cholinergic inhibition of N-type calcium currents in sympathetic neurons. European Journal of Neuroscience, 1998, 10, 1654-1666.	1.2	71
322	New Aspects of G-Protein-Coupled Receptor Signalling and Regulation. Trends in Endocrinology and Metabolism, 1998, 9, 13-19.	3.1	22
323	Human D2 and D4 dopamine receptors couple through Î²Î³ G-protein subunits to inwardly rectifying K+ channels (GIRK1) in a Xenopus oocyte expression system: selective antagonism by L-741,626 and L-745,870 respectively. Neuropharmacology, 1998, 37, 983-987.	2.0	44
324	Quantitative analysis of a cysteine351glycine mutation in the G protein Gi1Î±: effect on Î±2A-adrenoceptor-Gi1Î± fusion protein activation. FEBS Letters, 1998, 428, 17-22.	1.3	11

#	Article	IF	Citations
325	Loss of activation of Gsbut not Gifollowing expression of an Î±2A-adrenoceptor-Gi1Î± fusion protein. FEBS Letters, 1998, 436, 46-50.	1.3	14
326	Hydrophobicity of Residue351of the G Protein Gi1Î± Determines the Extent of Activation by the Î±2A-Adrenoceptorâ€. Biochemistry, 1998, 37, 11555-11562.	1.2	87
327	Agonist Occupation of an Î±2A-Adrenoreceptor-Gi1Î± Fusion Protein Results in Activation of Both Receptor-linked and Endogenous Gi Proteins. Journal of Biological Chemistry, 1998, 273, 10367-10375.	1.6	58
328	Agonist-Induced Endocytosis and Recycling of the Gonadotropin-Releasing Hormone Receptor: Effect of Î²-Arrestin on Internalization Kinetics. Molecular Endocrinology, 1998, 12, 1818-1829.	3.7	105
329	Real Time Visualization of Agonist-mediated Redistribution and Internalization of a Green Fluorescent Protein-tagged Form of the Thyrotropin-releasing Hormone Receptor. Journal of Biological Chemistry, 1998, 273, 24000-24008.	1.6	57
330	Agonist-induced Internalization of the G Protein G11Î± and Thyrotropin-releasing Hormone Receptors Proceed on Different Time Scales. Journal of Biological Chemistry, 1998, 273, 21699-21707.	1.6	42
331	Agonist-Mediated Turnover of G-Protein Î±-Subunit Palmitoyl Groups: Role in Membrane Insertion. , 1998, 88, 241-248.		2
332	Selective Activation of a Chimeric Gi1/GsG Protein Î± Subunit by the Human IP Prostanoid Receptor: Analysis Using Agonist Stimulation of High Affinity GTPase Activity and [35S]Guanosine-5â€²-O-(3-thio)triphosphate Binding. Molecular Pharmacology, 1998, 54, 249-257.	1.0	21
333	The Î± Subunit of GqContributes to Muscarinic Inhibition of the M-Type Potassium Current in Sympathetic Neurons. Journal of Neuroscience, 1998, 18, 4521-4531.	1.7	79
334	Agonist-Induced Endocytosis and Recycling of the Gonadotropin-Releasing Hormone Receptor: Effect of Â-Arrestin on Internalization Kinetics. Molecular Endocrinology, 1998, 12, 1818-1829.	3.7	68
335	Rescue of Functional Interactions between the Î±2A-Adrenoreceptor and Acylation-resistant Forms of Gi1Î± by Expressing the Proteins from Chimeric Open Reading Frames. Journal of Biological Chemistry, 1997, 272, 24673-24678.	1.6	48
336	Interactions of the Î±2A-adrenoceptor with multiple Gi-family G-proteins: studies with pertussis toxin-resistant G-protein mutants. Biochemical Journal, 1997, 321, 721-728.	1.7	76
337	Measurement of agonist-induced guanine nucleotide turnover by the G-protein Gi1Î± when constrained within an Î±2A-adrenoceptor-Gi1Î± fusion protein. Biochemical Journal, 1997, 325, 17-21.	1.7	51
338	Mitogenic signalling by Î´ opioid receptors expressed in Rat-1 fibroblasts involves activation of the p70s6k/p85s6k S6 kinase. Biochemical Journal, 1997, 325, 217-222.	1.7	34
339	Up-regulation of the levels of expression and function of a constitutively active mutant of the hamster Î±1B-adrenoceptor by ligands that act as inverse agonists. Biochemical Journal, 1997, 325, 733-739.	1.7	68
340	A Cysteine-3 to Serine Mutation of the G-Protein Gi1Î± Abrogates Functional Activation by the Î±2A-Adrenoceptor but Not Interactions with the Î²Î³ Complex. Biochemistry, 1997, 36, 10620-10629.	1.2	23
341	Interaction of the G-protein G11Î± with receptors and phosphoinositidase C:. FEBS Letters, 1997, 407, 257-260.	1.3	20
342	Measurement of agonist efficacy using an Î±2A-adrenoceptor-Gi1Î± fusion protein. FEBS Letters, 1997, 419, 141-146.	1.3	34

#	Article	IF	Citations
343	Inverse agonism and the regulation of receptor number. Trends in Pharmacological Sciences, 1997, 18, 468-474.	4.0	134
344	Selective interactions of Î¼-opioid receptors with pertussis toxin-sensitive G proteins: involvement of the third intracellular loop and the c-terminal tail in coupling. Biochimica Et Biophysica Acta - Molecular Cell Research, 1997, 1359, 263-274.	1.9	41
345	Is Promiscuity of G Protein Interaction an Issue in the Classification of Receptors?. Annals of the New York Academy of Sciences, 1997, 812, 126-132.	1.8	9
346	Agonist-Mediated Tyrosine Phosphorylation of Isoforms of the Shc Adapter Protein by the Î´ Opioid Receptor. Cellular Signalling, 1997, 9, 423-429.	1.7	12
347	Tailoring cAMP-signalling responses through isoform multiplicity. Trends in Biochemical Sciences, 1997, 22, 217-224.	3.7	417
348	A Bioluminescent Assay for Agonist Activity at Potentially Any G-Protein-Coupled Receptor. Analytical Biochemistry, 1997, 252, 115-126.	1.1	201
349	Regulation of Spontaneous Activity of the Î´â€Opioid Receptor: Studies of Inverse Agonism in Intact Cells. Journal of Neurochemistry, 1997, 69, 2115-2122.	2.1	43
350	G16 as a universal G protein adapter: implications for agonist screening strategies. Trends in Pharmacological Sciences, 1996, 17, 235-237.	4.0	114
351	Overexpression of GsÎ± in NG108-15, neuroblastoma X glioma cells: effects on receptor regulation of the stimulatory adenylyl cyclase cascade. FEBS Letters, 1996, 397, 325-330.	1.3	11
352	Up-regulation of a constitutively active form of theÎ²2-adrenoceptor by sustained treatment with inverse agonists but not antagonists. FEBS Letters, 1996, 399, 108-112.	1.3	35
353	Endocrine disorders associated with mutations in guanine nucleotide binding proteins. Bailliere's Clinical Endocrinology and Metabolism, 1996, 10, 177-187.	1.0	5
354	Chapter 16 Activation, cellular redistribution and enhanced degradation of the G proteins Gqs and G11 by endogenously expressed and transfected phospholipase C-coupled muscarinic m1 acetylcholine receptors. Progress in Brain Research, 1996, 109, 181-187.	0.9	7
355	Cold-induced reduction in GiÎ± proteins in brown adipose tissue. Effects on the cellular hypersensitization to noradrenaline caused by pertussis-toxin treatment. Biochemical Journal, 1996, 314, 761-768.	1.7	12
356	Analysis of inverse agonism at the Î´ opioid receptor after expression in Rat 1 fibroblasts. Biochemical Journal, 1996, 315, 227-234.	1.7	45
357	Agonist regulation of adenylate cyclase activity in neuroblastoma Ã— glioma hybrid NG108-15 cells transfected to co-express adenylate cyclase type II and the Î²2-adrenoceptor. Evidence that adenylate cyclase is the limiting component for receptor-mediated stimulation of adenylate cyclase activity. Biochemical Journal, 1996, 318, 1033-1039.	1.7	40
358	A constitutively active mutant of the Î±1B-adrenergic receptor can cause greater agonist-dependent down-regulation of the G-proteins GqÎ± and G11Î± than the wild-type receptor. Biochemical Journal, 1996, 320, 79-86.	1.7	14
359	Agonist activation of p42 and p44 mitogen-activated protein kinases following expression of the mouse Î´ opioid receptor in Rat-1 fibroblasts: effects of receptor expression levels and comparisons with G-protein activation. Biochemical Journal, 1996, 320, 227-235.	1.7	83
360	Characterization of heterotrimeric G-proteins in adult Acanthocheilonema viteae. Biochemical Journal, 1996, 320, 459-466.	1.7	3

#	Article	IF	Citations
361	The stoichiometry of expression of protein components of the stimulatory adenylyl cyclase cascade and the regulation of information transfer. Cellular Signalling, 1996, 8, 87-95.	1.7	37
362	Wortmannin-sensitive Activation of p70 by Endogenous and Heterologously Expressed G -coupled Receptors. Journal of Biological Chemistry, 1996, 271, 8537-8540.	1.6	41
363	Mechanism of Gonadotrophin Releasing Hormone Receptor Mediated Regulation of G-Proteins in Clonal Pituitary Gonadotrophs. , 1996, , 193-201.		0
364	Cyclic AMP differentially regulates the expression of the Î±-subunits of Gs, Gq and G11 G-proteins and their mRNA levels in rat C6 glioma cells. Biochemical Society Transactions, 1995, 23, 10S-10S.	1.6	4
365	High level expression of mammalian G protein Î± subunit Gq subtypes in Escherichia coli. Biochemical Society Transactions, 1995, 23, 12S-12S.	1.6	0
366	Interaction of the Î²2-adrenoceptor with epitope-tagged GsÎ±in NG108-15 cells. Biochemical Society Transactions, 1995, 23, 7S-7S.	1.6	0
367	Agonist regulation of high affinity [3H] forskolin binding as a measure of GsÎ±- adenylyl cyclase interactions. Biochemical Society Transactions, 1995, 23, 8S-8S.	1.6	0
368	Palmitoylation negative mutants of murine G11Î± have decreased ability to interact with the plasma membrane when expressed in COS-1 cells. Biochemical Society Transactions, 1995, 23, 9S-9S.	1.6	4
369	Signalling characteristics of thyrotropin releasing hormone (TRH) receptor isoforms. Biochemical Society Transactions, 1995, 23, 11S-11S.	1.6	0
370	Go1Î± palmitoylation: Its contribution to Î±2C10 adrenoceptor - Go1Î± coupling. Biochemical Society Transactions, 1995, 23, 406S-406S.	1.6	0
371	The dynamic role of palmitoylation in signal transduction. Trends in Biochemical Sciences, 1995, 20, 181-186.	3.7	312
372	Regulation of cellular Gs? levels and basal adenylyl cyclase activity by expression of the ?2-adrenoceptor in neuroblastoma cell lines. Molecular and Cellular Biochemistry, 1995, 149-150, 213-216.	1.4	4
373	Melatonin Receptors Couple Through a Cholera Toxin-Sensitive Mechanism to Inhibit Cyclic AMP in the Ovine Pituitary. Journal of Neuroendocrinology, 1995, 7, 361-369.	1.2	37
374	Signal Sorting by G-Protein-Linked Receptors. Advances in Pharmacology, 1995, 32, 1-29.	1.2	22
375	Degradation of G11Î±/GqÎ± Is Accelerated by Agonist Occupancy of Î±1A/D, Î±1B, and Î±1C Adrenergic Receptors. Journal of Biological Chemistry, 1995, 270, 17196-17203.	1.6	36
376	Bradykinin excites rat sympathetic neurons by inhibition of M current through a mechanism involving B2 receptors and GÎ±q/11. Neuron, 1995, 14, 399-405.	3.8	132
377	Increased concentrations of proteins Gi1 and Gi2 in adipocytes from aged rats alter the sensitivity of adenylyl cyclase to inhibitory and stimulatory agonists. Metabolism: Clinical and Experimental, 1995, 44, 239-244.	1.5	6
378	Involvement of G-protein Î±il subunits in activation of G-protein gated inward rectifying K+ channels (GIRK1) by human NPY1 receptors. British Journal of Pharmacology, 1995, 116, 2346-2348.	2.7	17

#	Article	IF	Citations
379	Inverse agonism: pharmacological curiosity or potential therapeutic strategy?. Trends in Pharmacological Sciences, 1995, 16, 10-13.	4.0	270
380	The Use of Stably Transfected Cell Lines in the Analysis of Functional Interactions between GoÎ±1 & GiÎ±2 and the Î±2C10 Adrenoceptor. , 1995, , 99-113.		0
381	Identification of stable opioid receptor Go-protein complexes using GTP-binding protein selective antisera. , 1995, , 87-98.		0
382	Regulation of cellular GsÎ± levels and basal adenylyl cyclase activity by expression of the Î²2-adrenoceptor in neuroblastoma cell lines. , 1995, , 213-216.		0
383	Agonist-induced Transfer of the alpha Subunits of the Guanine-nucleotide-binding Regulatory Proteins Gq and G11, and of Muscarinic m1 Acetylcholine Receptors from Plasma Membranes to a Light-vesicular Membrane Fraction. FEBS Journal, 1994, 224, 455-462.	0.2	35
384	Quantitative stoichiometry of the proteins of the stimulatory arm of the adenylyl cyclase cascade in neuroblastoma x glioma hybrid, NG108-15 cells. FEBS Journal, 1994, 219, 135-143.	0.2	27
385	Concurrent specific immunological detection of both primate and rodent forms of the guanine nucleotide binding protein G11Î± following their coexpression. Biochimica Et Biophysica Acta - Molecular Cell Research, 1994, 1222, 369-374.	1.9	7
386	Guanine nucleotide regulatory protein alterations in young Milan hypertensive strain rats. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1994, 1225, 149-157.	1.8	10
387	Equivalent regulation of wild type and an epitope-tagged variant of GsÎ± by the IP prostanoid receptor following expression in neuroblastoma Ã— glioma hybrid, NG108-15, cells. FEBS Letters, 1994, 353, 231-234.	1.3	13
388	Receptor availability defines the extent of agonist-mediated G-protein down-regulation in neuroblastoma Ã— glioma hybrid cells transfected to express the Î²2-adrenoceptor. FEBS Letters, 1994, 355, 166-170.	1.3	2
389	[21] Specificity and functional applications of antipeptide antisera which identify G-protein Î± subunits. Methods in Enzymology, 1994, 237, 268-283.	0.4	12
390	Regional Distribution and Quantitative Measurement of the Phosphoinositidase C-Linked Guanine Nucleotide Binding Proteins G1? and Gq? in Rat Brain. Journal of Neurochemistry, 1993, 61, 845-851.	2.1	54
391	An arginine residue is the site of receptor-stimulated, cholera toxin-catalysed ADP-ribosylation of pertussis toxin-sensitive G-proteins. Cellular Signalling, 1993, 5, 485-493.	1.7	4
392	The human muscarinic M1 acetylcholine receptor, when expressed in CHO cells, activates and downregulates both GqÎ± and G11Î± equally and non-selectively. FEBS Letters, 1993, 324, 241-245.	1.3	40
393	Alterations in the activity of adenylate cyclase and high affinity GTPase in Alzheimer's disease. Brain Research, 1993, 622, 35-42.	1.1	35
394	Immunological Analysis of Glucose Transporters Expressed in Different Regions of the Rat Brain and Central Nervous System. Biochemical and Biophysical Research Communications, 1993, 192, 1297-1302.	1.0	138
395	Mechanisms of multifunctional signalling by G protein-linked receptors. Trends in Pharmacological Sciences, 1993, 14, 239-244.	4.0	150
396	Agonist regulation of cellular G protein levels and distribution: mechanisms and functional implications. Trends in Pharmacological Sciences, 1993, 14, 413-418.	4.0	122

#	Article	IF	Citations
397	Distribution and relative levels of expression of the phosphoinositidase-C-linked G-proteins GqÎ± and G11Î±: Absence of G11Î± in human platelets and haemopoietically derived cell lines. Biochimica Et Biophysica Acta - Molecular Cell Research, 1993, 1179, 208-212.	1.9	43
398	Agonist regulation of cellular levels of the stimulatory guanine nucleotide-binding protein, Gs, in wild type and transfected neuroblastoma-glioma hybrid NG108-15 cells. Biochemical Society Transactions, 1993, 21, 432-435.	1.6	13
399	Agonist activation of transfected human M1 muscarinic acetylcholine receptor in Chinese hamster ovary cells results in concurrent downregulation of GqÎ± and G11Î±. Biochemical Society Transactions, 1993, 21, 497S-497S.	1.6	1
400	Activation of the gonadotropin releasing hormone receptor of Î±T3 cells results in downregulation of the Î± subunits of both Gq/G11. Biochemical Society Transactions, 1993, 21, 498S-498S.	1.6	2
401	G-proteins in experimental hypertension: a study of spontaneously hypertensive rat myocardial and renal cortical plasma membranes. Journal of Hypertension, 1993, 11, 365-372.	0.3	27
402	38 Alterations in the levels and function of guanine nucleotide regulatory proteins in Milan hypertensive rats. Journal of Hypertension, 1993, 11, S412.	0.3	0
403	G-proteins in essential hypertension: a study of human platelet plasma membranes. Journal of Hypertension, 1993, 11, 543-550.	0.3	20
404	Identification and Analysis of Function of Heterotrimeric Guanine Nucleotide-Binding Proteins Expressed in Neural Tissue. , 1992, , 1-56.		2
405	Multiple heterotrimeric guanine nucleotide binding proteins: roles in the determination of cellular signalling specificity. Biochemical Society Transactions, 1992, 20, 135-140.	1.6	8
406	Guanine nucleotide regulatory protein levels and function in spontaneously hypertensive rat vascular smooth-muscle cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 1992, 1136, 290-296.	1.9	31
407	Immunological identification of the Î± subunit of G13, a novel guanine nucleotide binding protein. FEBS Letters, 1992, 297, 186-188.	1.3	22
408	Altered G-protein expression and adenylate cyclase activity in platelets of non-insulin-dependent diabetic (NIDDM) male subjects. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1991, 1096, 127-133.	1.8	41
409	Widespread distribution of GqÎ±/GllÎ± detected immunologically by an antipeptide antiserum directed against the predicted C-terminal decapeptide. FEBS Letters, 1991, 287, 171-174.	1.3	59
410	Agonist control of G-protein levels. Trends in Pharmacological Sciences, 1991, 12, 207-209.	4.0	63
411	U937 cell differentiation: G protein alterations and interaction with the chemotactic peptide receptor. Biochemical Society Transactions, 1991, 19, 98S-98S.	1.6	0
412	Signal transduction in Rat-1 fibroblasts expressing high levels of the Î±2-C10 adrenergic receptor. Biochemical Society Transactions, 1991, 19, 102S-102S.	1.6	0
413	Effects of prolonged treatment of adipocytes with PGE1, N6-phenylisopropyl adenosine and nicotinic acid on G-proteins and antilipolytic sensitivity. Biochemical Society Transactions, 1991, 19, 212S-212S.	1.6	5
414	Prostanoid-mediated downregulation of Gs in NG108â€“15 cells. Biochemical Society Transactions, 1991, 19, 81S-81S.	1.6	10

#	Article	IF	Citations
415	Robustness of G Proteins in Alzheimer's Disease: An Immunoblot Study. Journal of Neurochemistry, 1991, 57, 9-14.	2.1	70
416	Expression of Two Isoforms of the Guanine Nucleotide Binding Protein,Go, IN NG108â€“15 Neuroglioma Cells. , 1991, , 221-235.		0
417	Identification and analysis of two distinct isoforms of the guanine nucleotide-binding protein G0 in NG108-15 cells. Biochemical Society Transactions, 1990, 18, 396-399.	1.6	1
418	Down-regulation of the Î±-subunits of Gi subtypes by prolonged incubation of adipocytes with N6-phenylisopropyl adenosine. Biochemical Society Transactions, 1990, 18, 487-487.	1.6	2
419	Identification of Two Distinct Isoforms of the Guanine Nucleotide Binding Protein Goin Neuroblastoma Ã— Glioma Hybrid Cells: Independent Regulation During Cyclic AMP-Induced Differentiation. Journal of Neurochemistry, 1990, 55, 1890-1898.	2.1	53
420	Chronic exposure of rat glioma C6 cells to cholera toxin induces loss of the Î±-subunit of the stimulatory guanine nucleotide-binding protein (Gs). European Journal of Pharmacology, 1990, 188, 203-209.	2.7	17
421	Biphasic regulation of adenylate cyclase by cholera toxin in neuroblastoma Ã— glioma hybrid cells is due to the activation and subsequent loss of the Î± subunit of the stimulatory GTP binding proteins (Gs). Cellular Signalling, 1990, 2, 139-151.	1.7	19
422	Guanine nucleotide binding proteins in neuroblastoma Ã— glioma hybrid, NG108-15, cells. regulation of expression and function. International Journal of Biochemistry & Cell Biology, 1990, 22, 701-707.	0.8	11
423	Insulin activates glycerol-3-phosphate acyltransferase (de novo phosphatidic acid synthesis) through a phospholipid-derived mediator. Apparent involvement of Gi.alpha. and activation of a phospholipase C. Biochemistry, 1990, 29, 8735-8740.	1.2	73
424	Phosphorylation of Gi in intact cells. Trends in Biochemical Sciences, 1990, 15, 13.	3.7	2
425	Stimulus-response coupling in FMLP-stimulated U937 monocytes. Biochimica Et Biophysica Acta - Molecular Cell Research, 1990, 1051, 71-77.	1.9	13
426	The Î±2B adrenergic receptor of undifferentiated neuroblastoma Ã— glioma hybrid NG108-15 cells, interacts directly with the guanine nucleotide binding protein, Gi2. FEBS Letters, 1990, 269, 430-434.	1.3	25
427	Multiple defects occur in the guanine nucleotide regulatory protein system in liver plasma membranes of obese (fa/fa) but not lean (Fa/Fa) zucker rats: Loss of functional G1 and abnormal Gs function. Cellular Signalling, 1989, 1, 9-22.	1.7	42
428	Foetal calf serum enhances cholera toxin-catalysed ADP-ribosylation of the pertussis toxin-sensitive guanine nucleotide binding protein, Gi2, in rat glioma C6BU1 cells. Cellular Signalling, 1989, 1, 65-74.	1.7	10
429	Tissue distribution and subcellular location of guanine nucleotide binding proteins: â€" Implications for cellular signalling. Cellular Signalling, 1989, 1, 411-419.	1.7	14
430	Antibodies to the GTP binding protein, Go, antagonize noradrenaline-induced calcium current inhibition in NG108-15 hybrid cells. Neuron, 1989, 3, 177-182.	3.8	165
431	G-proteins and second messengers in mitogenesis. Progress in Growth Factor Research, 1989, 1, 161-177.	1.7	3
432	Binding to GDP-agarose identifies a novel 60kDa substrate for the insulin receptor tyrosyl kinase in mouse NIH-3T3 cells expressing high concentrations of the human insulin receptor. Biochemical and Biophysical Research Communications, 1989, 158, 743-748.	1.0	11

#	Article	IF	Citations
433	Identification of both Gi 2 and a novel, immunologically distinct, form of Go in rat myometrial membranes. FEBS Letters, 1989, 244, 411-416.	1.3	29
434	Elevated levels of the guanine nucleotide binding protein, Go , are associated with differentiation of neuroblastoma Ã— glioma hybrid cells. FEBS Letters, 1989, 244, 113-118.	1.3	24
435	Treatment of intact hepatocytes with either the phorbol ester TPA or glucagon elicits the phosphorylation and functional inactivation of the inhibitory guanine nucleotide regulatory protein Gi. FEBS Letters, 1989, 243, 77-82.	1.3	91
436	Expression of G-protein Î²-subunit in lean and obese Zucker rats and streptozotocin-induced diabetic and normal rats. Biochemical Society Transactions, 1989, 17, 667-668.	1.6	1
437	Guanine nucleotide regulatory proteins in insulin's action and in diabetes. Biochemical Society Transactions, 1989, 17, 627-629.	1.6	15
438	Immunochemical and electrophoretic characterization of the major pertussis toxin substrate of the RAW264 macrophage cell line. Biochemistry, 1988, 27, 2040-2046.	1.2	37
439	Purification of heterotrimeric GTP-binding proteins from brain: identification of a novel form of Go. Biochemistry, 1988, 27, 7085-7090.	1.2	160
440	GTP analogues cause release of the alpha subunit of the GTP binding protein, GO, from the plasma membrane of NG108-15 cells. Biochemical and Biophysical Research Communications, 1988, 152, 243-251.	1.0	42
441	SELECTIVE DEFICIENCY OF GUANINE NUCLEOTIDE-BINDING PROTEIN Go IN TWO DOPAMINE-RESISTANT PITUITARY TUMORS. Endocrinology, 1988, 122, 1176-1178.	1.4	50
442	The use of anti-peptide antisera to probe interactions between receptors and guanine nucleotide binding proteins. Biochemical Society Transactions, 1988, 16, 434-437.	1.6	12
443	The use of specific antibodies to identify and quantify guanine nucleotide-binding proteins. Biochemical Society Transactions, 1987, 15, 42-45.	1.6	18
444	Guanine nucleotide regulation of the pertussis and cholera toxin substrates of rat glioma C6 BU1 cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 1987, 929, 197-202.	1.9	31
445	Differential distribution of signal-transducing G-proteins in retina. Brain Research, 1987, 423, 237-246.	1.1	22
446	The insulin receptor tyrosyl kinase phosphorylates holomeric forms of the guanine nucleotide regulatory proteins Giand Go. FEBS Letters, 1987, 212, 281-288.	1.3	126
447	GTP-Binding proteins in brain and neutrophil are tethered to the plasma membrane via their amino termini. Biochemical and Biophysical Research Communications, 1987, 148, 1398-1405.	1.0	52
448	Tissue-specific regulation of GTP-binding protein and muscarinic acetylcholine receptor levels during cardiac development. Biochemistry, 1987, 26, 4876-4884.	1.2	47
449	Abolition of the expression of inhibitory guanine nucleotide regulatory protein Gi activity in diabetes. Nature, 1987, 327, 229-232.	13.7	248
450	THE USE OF SPECIFIC ANTISERA TO STUDY THE DEVELOPMENTAL REGULATION OF GUANINE NUCLEOTIDE BINDING PROTEINS. , 1987, , 415-418.		1

#	Article	IF	Citations
451	The GTP-binding regulatory proteins of neuroblastoma Ã— glioma, NG108-15, and glioma, C6, cells. FEBS Letters, 1986, 195, 225-230.	1.3	87
452	Detection of the major pertussis toxin substrate of human leukocytes with antisera raised against synthetic peptides. FEBS Letters, 1986, 209, 352-356.	1.3	53
453	Changes in the guanine nucleotide-binding proteins, Giand go, during differentiation of 3T3-L1 cells. FEBS Letters, 1986, 199, 103-106.	1.3	50
454	Use of specific antibodies to quantitate the guanine nucleotide-binding protein Go in brain.. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 2258-2262.	3.3	157
455	Antibodies against the carboxyl-terminal 5-kDa peptide of the alpha subunit of transducin crossreact with the 40-kDa but not the 39-kDa guanine nucleotide binding protein from brain.. Proceedings of the National Academy of Sciences of the United States of America, 1985, 82, 4095-4099.	3.3	98
456	Use of [3H]Triphenylmethylphosphomum Cation for Estimating Membrane Potential in Neuroblastoma Cells. Journal of Neurochemistry, 1984, 43, 1515-1521.	2.1	9
457	Muscarinic Acetylcholine Receptors in Neuroblastoma Cells: Lack of Effect of Veratrum Alkaloids on Receptor Number. Journal of Neurochemistry, 1984, 43, 33-41.	2.1	7
458	Reduction in accumulation of [3H]triphenylmethylphosphonium cation in neuroblastoma cells caused by optical probes of membrane potential. Biochimica Et Biophysica Acta - Molecular Cell Research, 1983, 762, 585-592.	1.9	5
459	Apparent down-regulation of muscarinic acetylcholine receptors of neuroblastoma cells by pilocarpine is due to occluded agonist. European Journal of Pharmacology, 1983, 91, 223-228.	1.7	8
460	The Use of Biochemical Methods for Estimating Membrane Potential. Progress in Brain Research, 1982, 55, 321-329.	0.9	5
461	The use of lipophilic anions to facilitate uptake of triphenylmethylphosphonium cation in membrane-potential studies in neuroblastoma cells. Biochemical Society Transactions, 1982, 10, 375-376.	1.6	1
462	The effect of sodium channel activators on muscarinic receptors of neuroblastoma cells. FEBS Letters, 1982, 148, 39-43.	1.3	6
463	Biochemical estimation of membrane potential in neuroblastoma cells. Biochemical Society Transactions, 1981, 9, 414-415.	1.6	8
464	Functional studies of isolated GPCR-G protein complexes in the membrane bilayer of lipoprotein particles. , 0, , 32-52.		0
465	Time-resolved FRET approaches to study GPCR complexes. , 0, , 67-89.		2
466	Signaling of dopamine receptor homo- and heterooligomers. , 0, , 90-110.		0
467	Functional consequences of chemokine receptor dimerization. , 0, , 111-124.		0
468	Kinetics of GPCR, G protein, and effector activation. , 0, , 145-158.		0

#	Article	IF	Citations
469	Adenylyl cyclase isoform-specific signaling of GPCRs. , 0, , 189-216.		3
470	G protein-independent and Î² arrestin-dependent GPCR signaling. , 0, , 217-230.		0
471	Assays to read GPCR modulation and signaling. , 0, , 231-246.		0
472	7TM receptor functional selectivity. , 0, , 270-286.		0